About /gebrüderheitz

This author has not yet filled in any details.
So far /gebrüderheitz has created 2 blog entries.

May 2017

Press Release CellGenix – May

CellGenix appoints leading experts to scientific advisory board

Freiburg, Germany, May 15, 2017 – CellGenix, a global leader in providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, today announced the appointment of highly experienced and internationally respected experts in the field of cell and gene therapy to its Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to CellGenix as it continues to develop high quality raw materials used worldwide in cell and gene therapy and regenerative medicine.

“We are delighted to have attracted these renowned experts to the SAB,” says Prof. Dr. Felicia Rosenthal, CEO of CellGenix. “They join at an exciting time for CellGenix as the field is advancing rapidly and we are increasing our R&D investment. We are convinced that the background and experience of our SAB members will bring new ideas for our product development pipeline. Their input is especially welcome as we are working on various promising products for the future.”

The members of CellGenix’ Scientific Advisory Board are:

  • Cliona Rooney, Ph.D., is a Professor in the Center for Cell and Gene Therapy at Baylor College of Medicine. Prof. Rooney brings over 20 years of expertise in the field of T cell immunotherapy for virus-associated diseases and cancer. She was instrumental in the development of T-cell therapies virus-specific T-cells in the stem cell transplant setting and has further developed and refined antigen-specific T-cells for the treatment of cancer. Her current interests are in gene modifications and other strategies to render T-cells effective within an immunosuppressive microenvironment.
  • Mitchell H. Finer, Ph.D., brings three decades of experience in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, where he helped to advance products from conception through phase III clinical programs.  Dr. Finer founded Oncorus and currently serves as CEO and CSO. In 2015 he joined MPM Capital as Managing Director and is a member of the board of directors of MPM portfolio company Semma Therapeutics. Prior to MPM, Dr. Finer served as CSO of bluebird bio, where he was responsible for strategic elaboration of bluebird’s gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of CAR-T and genome engineering programs.
  • Anthony Davies, Ph.D., is the founder and executive chairman of Dark Horse Consulting, a consultancy agency focused on CMC and product development issues in monoclonal antibody and cell and gene therapies. Dr. Davies brings along more than two decades of experience in the cell and gene therapy field. Over this period he has held positions of increasing responsibility at companies including Onyx Pharmaceuticals, Geron Corporation and Capricor.

press release

April 2017

CellGenix Lectures – Prof. Dr. Evelyn Ullrich

Recent advances in NK cell translational research and clinical application in malignant diseases

We are excited to announce the third CellGenix Lecture given by Prof. Dr. Evelyn Ullrich. She will present recent results from translational NK cell research an give an overview on NK cell clinical studies. With our CellGenix Lectures we want to provide insights in the latest advances in the cell and gene therapy, and the regenerative medicine field.

Abstract
Natural killer (NK) cells are a promising tool for the use in immunotherapy, since they efficiently recognize and kill tumor cells. For adoptive cell therapy, NK cells from different sources can be stimulated with cytokines and accessory or feeder cells. Clinical studies exploiting the impact of NK cells in the context of hematopoietic stem cell transplantation (HSCT) have provided promising results due to their antitumor capability supporting the graft-versus-leukemia effect (GVL) without causing graft-versus-host disease (GVHD) which is one of the most severe complications in allogeneic HSCT. Furthermore, remarkable advances have been made in the development of CAR NK cell technologies.

Speaker
Prof. Dr. Evelyn Ullrich
Head of Cellular Immunology
Department of Pediatric Stem Cell Transplantation and Immunology,
Johann Wolfgang Goethe-University, Frankfurt/Main

When
Thursday, April 27, 2017
17:00-18:00 p.m., followed by a drinks reception with pretzels and wine

Where
CellGenix GmbH
Am Flughafen 16
79108 Freiburg

We would be happy to welcome you at our lecture. Please register for free via Lectures@cellgenix.com or T: 0761/88 88 9-0.

 

Where are you located?

Note: You have to select a country.